GenSight Biologics Launches Newsletter for Retail Investors

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today published the first issue of a company newsletter aimed at retail investors in France. The quarterly newsletter will be published in French and will be available via the company’s website and by subscription. “W